Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 555-559

  Epple, Hans Jörg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunosuppressive therapy, infection prevention; Inflammatory bowel disease, infectious complications; Non therapy dependent infections; Therapy dependent infections

Indexed keywords

ACICLOVIR; ATOVAQUONE; AZATHIOPRINE; CHICKENPOX VACCINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; INFLUENZA VACCINE; ISONIAZID; METHOTREXATE; PENTAMIDINE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; VALACICLOVIR;

ABSCESS; ASPERGILLOSIS; ASPERGILLUS; BACTERIAL INFECTION; CANDIDIASIS; CHEMOPROPHYLAXIS; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CRYPTOCOCCUS; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; ENTERITIS; EPSTEIN BARR VIRUS; GASTROENTERITIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTIOUS COMPLICATION; LEUKOPENIA; LISTERIOSIS; MALNUTRITION; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOSIS; NONHUMAN; PATHOGENESIS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; TOXOPLASMA; TOXOPLASMOSIS; TUBERCULOSIS; URINARY TRACT INFECTION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

COMMUNICABLE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

EID: 70449488916     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233297     Document Type: Review

References (28)

1. Ekbom A, Helmick CG, Zack M, et al: Survival and causes of death in patients with inflammatory bowel disease: a populationbased study. Gastroenterology 1992; 103: 954-960.
2. Hutfless SM, Weng X, Liu L, et al: Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007; 133: 1779-1786.
3. Jess T, Loftus EV Jr, Harmsen WS, et al: Survival and cause specific mortality in patients with inflammatory bowel disease: a longterm outcome study in Olmsted County, Minnesota, 1940-2004. Gut 2006; 55: 1248-1254.
4. Jess T, Gamborg M, Munkholm P, et al: Overall and cause-specific mortality in ulcerative colitis: meta-analysis of populationbased inception cohort studies. Am J Gastroenterol 2007; 102: 609-617.
5. Persson PG, Bernell O, Leijonmarck CE, et al: Survival and cause-specific mortality in inflammatory bowel disease: a populationbased cohort study. Gastroenterology 1996; 110: 1339-1345.
6. Winther KV, Jess T, Langholz E, et al: Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003; 125: 1576-1582.
7. Aberra FN, Lichtenstein GR: Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 685-695.
8. Hurst RD, Molinari M, Chung TP, et al: Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohn's disease. Surgery 1997; 122: 661-668.
9. Keighley MR, Eastwood D, Ambrose NS, et al: Incidence and microbiology of abdominal and pelvic abscess in Crohn's disease. Gastroenterology 1982; 83: 1271-1275.
10. Mir-Madjlessi SH, McHenry MC, Farmer RG: Liver abscess in Crohn's disease. Report of four cases and review of the literature. Gastroenterology 1986; 91: 987-993.
11. Schwartz DA, Wiersema MJ, Dudiak KM, et al: A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001; 121: 1064-1072.
12. Ben-Ami H, Ginesin Y, Behar DM, et al: Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can J Gastroenterol 2002; 16: 225-229.
13. Gruner JS, Sehon JK, Johnson LW: Diagnosis and management of enterovesical fistulas in patients with Crohn's disease. Am Surg 2002; 68: 714-719.
14. Mylonaki M, Langmead L, Pantes A, et al: Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775-778.
15. Hermens DJ, Miner PB Jr: Exacerbation of ulcerative colitis. Gastroenterology 1991; 101: 254-262.
16. Kochhar R, Ayyagari A, Goenka MK, et al: Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile . J Clin Gastroenterol 1993; 16: 26-30.
17. Weber P, Koch M, Heizmann WR, et al: Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 302-308.
18. Szilagyi A, Gerson M, Mendelson J, et al: Salmonella infections complicating inflammatory bowel disease. J Clin Gastroenterol 1985; 7: 251-255.
19. Ruigomez A, Garcia Rodriguez LA, Panes J: Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 2007; 5: 465-469.
20. Porter CK, Tribble DR, Aliaga PA, et al: Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008; 135: 781-786.
21. Meyer AM, Ramzan NN, Loftus EV Jr, et al: The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004; 38: 772-775.
22. Issa M, Ananthakrishnan AN, Binion DG: Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432-1442.
23. Issa M, Vijayapal A, Graham MB, et al: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351.
24. Ananthakrishnan AN, McGinley EL, Binion DG: Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-210.
25. Toruner M, Loftus EV, Jr., Harmsen WS, et al: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936.
26. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al: Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-558.
27. Wallis RS, Broder MS, Wong JY, et al: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265.
28. Wallis RS. Anti-tuberculosis treatment and infliximab. Respir Med 2005; 99: 1620-1622.